NEW YORK, Nov 10 (Reuters) - Regeneron Pharmaceuticals Inc and French drugmaker Sanofi-aventis said on Tuesday they have expanded their partnership to develop a number of Regeneron's experimental ...

Sanofi, Regeneron eye $11B in Dupixent sales with ... The move will cause "no change" to their ongoing partnership, the companies said. Sanofi will retain about 400,000 shares in Regeneron stock ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

Sanofi recognizes all revenue from antibodies in the partnership. The drug accounted for €10.7 billion (about $11.6 billion) in sales in 2023, up nearly 30% from the prior year, according to the ...

With support from Sanofi and Regeneron, Viz.ai will investigate the use of the Viz COPD module, a care acceleration solution that will leverage electronic health record (EHR) data and artificial ...

Sanofi expects Dupixent to achieve around €22 billion in sales in 2030. Regeneron recorded collaboration revenues of $1.18 billion from Sanofi during the first quarter of 2025, up 30% year over ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US ...

Regeneron and Sanofi on Tuesday said the new indication covers the treatment of patients weighing at least 139 ... and their inclusion on this site does not imply any form of partnership, ...

Sanofi SNY and Regeneron REGN announced encouraging data from the confirmatory phase III LIBERTY-CUPID C study evaluating their blockbuster drug Dupixent (dupilumab) in chronicspontaneous ...

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...

An experimental COPD medicine from Sanofi and Regeneron Pharmaceuticals produced mixed results in a pair of studies, the companies said Friday, sending both firms’ shares down in early and pre ...